CLINICAL_TRIALS trial_result · 2023-10-27

Clinical Trial Update: Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 [Phase 2]

Phase 2 results from a trial of ALXN1840 in Wilson disease report copper and molybdenum balance in participants. Results were posted on 2023-10-27.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Wilson Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-10-27